| Tuberculosis | NG33 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Caesarean birth | NG192 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Devices for remote monitoring of Parkinson's disease | DG51 | | |
| COVID-19 rapid guideline: managing the long-term effects of COVID-19 | NG188 | | |
| Skin cancer | QS130 | | |
| Pharyngeal electrical stimulation for neurogenic dysphagia | IPG781 | | |
| Temperature control to improve neurological outcomes after cardiac arrest | IPG782 | | |
| Neonatal infection | QS75 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Sebelipase alfa for treating Wolman disease | HST30 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | IPG780 | | |
| Bipolar disorder: assessment and management | CG185 | | |
| Epilepsies in children, young people and adults | QS211 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |